Gilead Sciences, Inc. GILD reported lower-than-expected first-quarter 2025 results. Adjusted earnings per share (EPS) of $1.81 missed the Zacks Consensus Estimate by a penny. In the year-ago quarter, ...

Real-world data indicated ART with DTG+3TC was effective and well tolerated among patients with HIV infection regardless of prior ART exposure.

The session titled “Defeating Cancer by Curing Infections” at European Society of Clinical Microbiology and Infectious ...

Lenacapavir could be a gamechanger in the fight against infection. But US funding cuts have thrown the rollout of the ...

The Trump Administration has gutted many areas of healthcare funding and research, especially in infectious diseases. One ...

Over 2 million people are currently living with Human immunodeficiency virus (HIV) in Nigeria and the latest data from the National Agency for the Control of AIDS (NACA) sheds new light on how the HIV ...

A new report from the National Agency for the Control of AIDS (NACA) has revealed that Rivers State currently has the highest ...

A team at UC San Francisco and Gladstone Institutes has developed new drug candidates that show great promise against the virus that causes COVID-19 and potentially other coronaviruses that could ...

A KFF Health News analysis underscores how the terminations have spared no part of the country, politically or geographically ...

This surge in infections in low- and middle-income countries would contribute up to 2.9 million more HIV ... (ART), the drugs ...